Navigation Links
Bacterin Announces First Quarter 2012 Revenue of $7.8 Million, Up 29% Year-over-Year, on Gross Margins of 76%, and 34% Reduction in Operating Loss
Date:5/3/2012

BELGRADE, Mont., May 3, 2012 /PRNewswire/ -- Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, today announced its financial results for the first quarter ended March 31, 2012:

 2012 Highlights:

  • Revenue increased 29% to $7.8 million, compared to the $6.0 million for the first quarter of 2011.
  • Operating loss decreased by 34% to $1.3 million, compared to an operating loss of $1.9 million in the first quarter of 2011.
  • Gross Margin was 76%, above the previous guidance of 70 to 75%, and compared to 83.5% in the first quarter of 2011
  • Inventory increased to $11.4 million, sequentially compared to $9.4 million in fourth quarter of 2011 as a result of the increase in the receipt of donor inventory and increased production efficiency.
  • April 4, 2012, a peer review article in Orthopedic Research and Reviews determined OsteoSponge® exhibits ideal properties for bone regeneration, similar to those of autograft (graft of patient's own bone) with a distinct advantage over autograft, in that there is no risk of complications at the harvest site or donor pain postoperatively.
  • Recent studies conducted at the Hospital for Special Surgery have shown the OsteoSelect DBM putty proved equivalent to autologous bone graft in the posterolateral intertransverse rabbit model.
  • On April 23, 2012, the Company secured an accounts receivable credit facility with Midcap Financial LLC and Silicon Valley Bank for up to $5 million through January 1, 2015 based upon a predetermined formula for borrowings of up to 80% of Bacterin's eligible accounts receivable, as defined in the credit and security agreement.
  • Secured third national GPO contract, a three-year agreement with  a leading heal
    '/>"/>

  • SOURCE Bacterin International Holdings, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine technology :

    1. Bacterin International Completes $3 Million Private Placement
    2. Bacterin International Introduces OsteoSelect(R) DBM Putty
    3. Bacterin International Secures Three-Year Agreement to Distribute Biologic Products to Broadlanes Network of Over 6,000 Medical Facilities
    4. Bacterin International Holdings, Inc. Completes Merger and $7.5 Million Raise
    5. Bacterin International Holdings, Inc. to Present at the 6th Annual Fall Growth Stock Conference Hosted by Security Research Associates, Inc.
    6. Bacterin International to Present at Singular Research 5th Annual Best of the Uncovereds Conference
    7. Bacterin International Holdings, Inc. Schedules Conference Call to Present Third Quarter 2010 Financial Results
    8. Bacterin International Holdings, Inc. Reports Third Quarter 2010 Financial Results
    9. Bacterin International Holdings to Present at the OneMedForum San Francisco 2011
    10. Bacterin International to Announce Launch of OsteoSponge®SC at American Academy of Orthopedic Surgeons 2011 Annual Meeting February 15-19
    11. Bacterin International Announces Major Orthopedic Hospital Group to Begin Use of OsteoSponge®SC
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/1/2015)... --NOWDiagnostics Inc., based in Springdale, Ark. , ... Canada , a move that brings the company ... have greater access to information concerning their health. ... blood-based rapid tests that allow health care providers to ... ailments and diseases. ZBx Corporation, a Toronto ...
    (Date:9/1/2015)... , Sept. 1, 2015  Dr. Cindy ... Labs , the cannabis testing subsidiary of DigiPath, Inc. ... Group about the lack of consistency in today,s ... online resource for medical cannabis information, she explained that ... because their lack of uniform requirements makes standardization impossible. ...
    (Date:9/1/2015)... 1, 2015   Alpha Imaging LLC , a leading distributor ... announced today that they have been awarded exclusive rights to ... in Michigan.   The new territory supplements Alpha Imaging,s existing Shimadzu sales ... Ohio , Indiana , ... , West Virginia , Delaware ...
    Breaking Medicine Technology:NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 2NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 3DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 2DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 3Alpha Imaging Expands Shimadzu Territory 2
    ... Medical Systems (NYSE: VAR ) today announced that ... N.A. to repurchase $250 million of its common stock under ... revolving credit facility with Bank of America, N.A. to increase ... Under the accelerated repurchase agreement, Varian will pay $250 ...
    ... Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced ... trial evaluating the safety and pharmacokinetics of dabigatran ... valves.(1) The 12-week study will compare three doses ... 300mg bid) to warfarin in patients with both ...
    Cached Medicine Technology:Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 2Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 3Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 2Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 3Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 4Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 5Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 6Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 7
    (Date:9/1/2015)... ... September 01, 2015 , ... ... (FDA) for the treatment of androgenic alopecia in adults, announces Miami-based medical device ... therapy cap, while also demonstrating its safety when used at home to combat ...
    (Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... physical therapy company, is pleased to announce their partnership with Apex Physical ... allows both groups to continue to provide kind, compassionate, and empathetic care to ...
    (Date:9/1/2015)... ... September 01, 2015 , ... From Aug. 17-21, Calvary Hospital hosted the ... 6-18. Calvary’s Camp Compass® has taken place at Kingsborough Community College in Brooklyn in ... of whom work for Calvary, and two junior counselors who were campers themselves just ...
    (Date:9/1/2015)... ... September 01, 2015 , ... ... to efficiently cure and prevent different malignancies. Some options for cancer treatment ... properties due to which distinctive approach is necessary for effective treatment. Several ...
    (Date:9/1/2015)... ... 01, 2015 , ... Negative pressure wound therapy (NPWT) entails ... remove exudates, fluid, and infectious materials to prepare the wound for healing and ... and canisters, etc.) is projected to expand continuously through 2021. , Rising patient ...
    Breaking Medicine News(10 mins):Health News:Capillus82™ Laser Therapy Cap Receives FDA Clearance for Treatment of Hair Loss 2Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 2Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 3Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 3Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 3
    ... “black box warning” to three asthma drugs//, Foradil, ... the manufacturers that the drug should carry clearly ... ,Adavir and Serevent are manufactured by ... the drug Foradil which contains a different long-acting ...
    ... for all chocolate lovers, as against the general thought ... that dark chocolate can actually improve heart function. ... dark chocolate consumption on blood vessel function in 17 ... these subjects exhibited a 7 % decrease in aortic ...
    ... People suffering from irritable bowel syndrome may be having ... bowel syndrome is one of the most common gastrointestinal ... abdominal pain and changed bowel habits with no particular ... for the condition. ,Scientists from St. George's ...
    ... early breast cancer// patients increased the risk of ... study published in Journal of clinical oncology reports ... higher than standard cumulative doses of epirubicin and ... myeloid leukemia (AML) or Myelodysplastic syndrome (MDS). ...
    ... believe it but science is skeptical about it.// However there ... healing. ,Some scientists also now are starting to ... others, influence our health. ,The new age healing mantra ... approach to wellness”, which unites the science of medicine with ...
    ... from injuries. However at times due to age or ... Researchers have identified a molecule that when is deficient, ... from University of Illinois-Chicago had reported in their findings ... and this may be targeted to treatment in cases ...
    Cached Medicine News:Health News:FDA gives “black box warning” against three asthma dru 2Health News:High-Dosage of Epirubicin and Cyclophosphamide may cause AML 2Health News:Link between Faith, Health and Healing 2Health News:Link between Faith, Health and Healing 3
    ... a whole blood hematology control manufactured specifically ... 120, and the Coulter AcT5diff instruments. The ... white cell differential, positioning the populations within ... systems. The product offers 105-day closed-vial stability ...
    ... assayed hematology control, offers complete assay values ... with the Coulter GENS, STKS, MAXM and ... stability, 105-day closed-vial stability and is available ... 4.0ml pierceable cap vial is compatible with ...
    Abiomed introduces its new intra-aortic balloon (IAB); an easy-to-insert, minimally invasive technology designed to enhance blood flow to the heart and other organs for patients with diminished heart...
    Diagnosoft HARP is designed for rapid analysis of tagged cardiac MR images using the HARP technology, which is packaged into an intuitive, easy-to-use graphic user interface....
    Medicine Products: